Foamix Pharmaceuticals Ltd. (FOMX) has 32 open-market insider trades by 10 insiders since 2018. The most active filer is David Domzalski, CEO.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Aharon Schwartz | Dir | — | 1 | $438K | 2020-03-09 |
| Ilan Hadar | CFO | — | 1 | $120K | 2020-03-09 |
| David Domzalski | CEO | — | 12 | $114K | 2020-03-09 |
| Matthew T. Wiley | CCO | — | 1 | $101K | 2020-03-09 |
| Anna Kazanchyan | Dir | — | 2 | $51K | 2020-03-09 |
| Stanley Hirsch | Dir | — | 1 | $31K | 2020-03-09 |
| Iain Stuart | Chief Scientific Officer | — | 4 | $27K | 2020-03-09 |
| Alvin D. Howard | VP Regulatory | — | 4 | $17K | 2018-11-19 |
| Mutya Harsch | CLO and General Counsel | — | 2 | $11K | 2020-03-09 |
| Russell P. Elliott | VP Drug Development | — | 4 | $7K | 2018-10-01 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Ilan Hadar | CFO | Sell | $153K | 2019-09-09 |
| Anna Kazanchyan | Director | Sell | $23K | 2019-08-26 |
| Anna Kazanchyan | Director | Sell | $2K | 2019-07-15 |
| Iain Stuart | Chief Scientific Officer | Sell | $2K | 2019-07-01 |
| Mutya Harsch | CLO and General Counsel | Sell | $2K | 2019-07-01 |
| David Domzalski | CEO | Sell | $8K | 2019-07-01 |
Companies that share insiders with FOMX, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Anna Kazanchyan | Director | Sell | $28K | 2019-05-20 |
| David Domzalski | CEO | Sell | $19K | 2019-04-01 |
| Mutya Harsch | CLO and General Counsel | Sell | $9K | 2019-04-01 |
| Iain Stuart | Chief Scientific Officer | Sell | $6K | 2019-04-01 |
| Matthew T. Wiley | CCO | Buy | $101K | 2019-03-05 |
| David Domzalski | CEO | Sell | $275 | 2018-12-03 |
| Aharon Schwartz | Director | Buy | $438K | 2018-11-26 |
| David Domzalski | CEO | Sell | $20K | 2018-11-19 |
| Alvin D. Howard | VP Regulatory | Sell | $13K | 2018-11-19 |